PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

June 24, 2010 | ISSUE NUMBER 154 VOL 8

Strategy
Pfizer Pulls Leukemia Treatment
Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?

Advertisement:
The Health Care Reform Opportunity: Implications and Recommendations for Life Sciences
Is health care reform a tough pill to swallow for your business? Although reform is changing the landscape, it is rife with opportunity. A report from Capgemini Consulting examines the challenges and implications resulting from health care reform and offers recommendations on how capitalize on the shifts within the industry. Download here

Study
GSK Scores High in Market Access
A new global report looks at which pharma companies are tops when it comes to offering medicines in emerging markets. Some of the big players are inching forward in a move towards access and transparency.

Global
HTA Concerns from European Drug Agency
The EMA's Thomas Lönngren has gone public with his disquiet over organizations such as NICE. But pharma still needs more allies to fight what it sees as the failings of the health technology assessment bodies, says Pharm Exec Europe's Brussels correspondent, Reflector.

New & Noteworthy
GSK Riding the Wave
A new "upstream" healthcare model may help deliver on the longstanding promise of personalized medicine.

// Ana Stancic was appointed to the board of K-V Pharmaceutical. // Gentris hired Rick Williams as its new CEO and named him to its board. // MonoSol appointed Eric Dadey SVP of pharmaceutical development. // Jennerex named Gregory Schafer SVP and CFO. He had been CFO at Onyx. // DKI Direct Appoints Greg Lewis As Chief Marketing Officer.

Jun 28–29 Clinical R&D Compliance Forum
Philadelphia, PA

Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA

Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

Dec 8—9 CMAC 2010 - Commercialization and Market Access Congress
Orlando, FL

A year and a half into President Obama's tenure, how do you view the effectiveness of the "new" FDA?

A FDA-NIH Road to Personalized Medicine

I Sell Therefore iPad?

AZ Settles Price Fixing Suit for $103 Million

Banner Ads Don’t Work? Bring on the Banners!


	Follow Pharm Exec on Twitter
	Follow Pharm Exec on Facebook

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.